Macular oedema – European Clinical Trials Information Network

Study on the Effects of RO7200220 for Adults and Children with Uveitic Macular Edema

Fri, 05 Jun 2026 10:50:30 +0000

This clinical trial is focused on studying a condition called Uveitic Macular Edema, which is a swelling in the central part of the retina, often associated with inflammation in the eye. The study is testing a treatment called RO7200220, also known by its code name IL6-Mab. This treatment is a type of medication known as a humanised IgG2 monoclonal antibody against interleukin-6, which is designed to target and reduce inflammation. The medication is given as a solution for injection directly into the eye.

The purpose of the study is to evaluate how effective and safe this treatment is for patients with Uveitic Macular Edema. Participants in the study will receive either the actual medication or a placebo. The study will monitor changes in vision and eye health over time, with particular attention to improvements in visual clarity and reductions in retinal swelling. The study will also assess the safety of the treatment by tracking any side effects that may occur.

Throughout the study, participants will have regular check-ups to measure their vision and eye condition. The study will last for a period of up to 52 weeks, during which the effects of the treatment will be closely observed. The goal is to determine if the treatment can significantly improve vision and reduce swelling in the retina for those affected by this condition.

Study on the Use of SB11 Pre-Filled Syringe for Patients with Wet Age-Related Macular Degeneration, Macular Edema from Retinal Vein Occlusion, or Myopic Choroidal Neovascularization

Wed, 29 Apr 2026 15:05:06 +0000

This clinical trial is focused on studying the usability of a new treatment method for eye conditions such as Neovascular Age-Related Macular Degeneration (AMD), Macular Edema Secondary to Retinal Vein Occlusion (RVO), and Myopic Choroidal Neovascularization (mCNV). The treatment being tested is a solution for injection called Byooviz, which contains the active substance ranibizumab. This study aims to evaluate how well healthcare professionals can use a pre-filled syringe to administer this treatment directly into the eye.

The study involves a single group of participants who will receive a one-time dose of the treatment. Healthcare professionals will follow specific instructions to prepare and give the injection. The main goal is to see how effectively these instructions can be followed. Participants will be monitored for any side effects or changes in their vision over a short period, typically up to a week after the injection.

Throughout the study, the focus will be on the ease of use of the pre-filled syringe and the safety of the treatment. The study will also look at any improvements in vision that may occur after the injection. This research is important for understanding how this new method of delivering ranibizumab can be used in treating these eye conditions effectively and safely.

Study on Ranibizumab Injections and Laser Treatment for Macular Edema in Central Retinal Vein Occlusion Patients

Wed, 29 Apr 2026 14:26:22 +0000

This clinical trial is focused on studying the treatment of macular edema caused by central retinal vein occlusion. Macular edema is a condition where fluid builds up in the macula, a part of the eye responsible for sharp vision, leading to vision problems. Central retinal vein occlusion occurs when the main vein in the retina becomes blocked, affecting blood flow and causing swelling. The treatment being studied involves the use of Ranibizumab, a medication that is injected into the eye to help reduce the swelling and improve vision. Ranibizumab is an anti-VEGF drug, which means it works by blocking a protein that can cause abnormal blood vessel growth and leakage in the eye.

The purpose of this study is to determine if the regular injections of Ranibizumab can be reduced or even stopped when combined with an early procedure called targeted peripheral laser photocoagulation. This procedure uses a laser to treat specific areas of the retina to help control the condition. Participants in the study will receive Ranibizumab injections, and some will also undergo the laser treatment. The study will monitor how long the injections are needed and whether the additional laser treatment can help reduce the need for them.

Throughout the study, participants will have regular check-ups to assess their vision and the thickness of the macula using a method called OCT (optical coherence tomography), which is a type of imaging test that provides detailed pictures of the retina. The study aims to find out if the combination of treatments can lead to a successful outcome, defined as a period of at least six months without needing further injections. The study will continue until 2026, allowing researchers to gather long-term data on the effectiveness of the treatment approach.

Study on the Effects of RO7200220 for Patients with Uveitic Macular Edema

Wed, 29 Apr 2026 14:24:33 +0000

This clinical trial is focused on studying a condition called Uveitic Macular Edema, which is a swelling in the central part of the retina, often associated with inflammation in the eye. The study is testing a treatment known as RO7200220, which is a type of medication called a humanised IgG2 monoclonal antibody against interleukin-6. This medication is given as a solution for injection directly into the eye, a method known as intravitreal use.

The purpose of the study is to evaluate how effective and safe this treatment is for patients with uveitic macular edema. Participants in the study will receive either the RO7200220 treatment or a placebo. The study will monitor changes in vision and eye health over time, with key assessments occurring at weeks 16, 20, and 52. The study will also look at how the medication moves through the body and its effects on the eye and overall health.

Throughout the study, participants will have regular check-ups to assess their vision and the thickness of the retina, as well as to monitor any side effects. The study aims to determine if the treatment can improve vision and reduce swelling in the retina, providing valuable information for managing uveitic macular edema.

Study on the Effectiveness and Safety of Aflibercept for Patients with Vision Loss Due to Macular Edema from Retinal Vein Blockage

Wed, 29 Apr 2026 14:23:28 +0000

This clinical trial is focused on studying a condition called macular edema, which is a swelling in the central part of the retina, known as the macula. This swelling is caused by a blocked vein in the retina, a condition referred to as retinal vein occlusion. The study is investigating the effectiveness and safety of a medication called aflibercept, which is given as an injection into the eye. Aflibercept is a protein-based treatment that helps reduce swelling and improve vision.

The purpose of the study is to compare two different doses of aflibercept. One group of participants will receive 8 mg of aflibercept every 8 weeks, while another group will receive 2 mg every 4 weeks. The study aims to determine if the higher dose given less frequently is as effective as the lower dose given more frequently. Participants will receive injections over a period of time, and their vision will be monitored to see how it changes with the treatment.

Throughout the study, participants will have their vision tested using a method called the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score, which measures how well they can see letters on a chart. The study will also track the number of injections participants receive and any side effects they may experience. The goal is to find the best treatment option for improving vision in people with macular edema due to retinal vein occlusion.